Core Viewpoint - The implementation of the national centralized procurement policy will significantly enhance the quality of medication for patients and optimize the clinical medication structure, with an average price reduction exceeding 60% for the selected drugs [1][2]. Group 1: Centralized Procurement Details - The centralized procurement covers 62 types of drugs, addressing treatment areas such as hypertension, diabetes, tumors, cardiovascular diseases, infections, and mental illnesses [1]. - High-value drugs and clinically scarce drugs are included, such as Doxorubicin Liposome Injection for breast cancer and Norepinephrine Bitartrate Injection for clinical shortages [1]. - Over 50 drug varieties, including Terbutaline Sulfate Injection and Linagliptin Tablets, have price reductions exceeding 90% [1]. Group 2: Impact on Patient Care - The policy will promote the replacement of unapproved drugs with those that have passed the national quality and efficacy consistency evaluation, thereby improving medication safety and efficacy [2]. - For instance, Doxorubicin Liposome Injection significantly reduces the incidence of adverse reactions compared to traditional formulations, enhancing medication safety [2]. - The inclusion of Macitentan Tablets for pulmonary arterial hypertension provides more treatment options for rare disease patients [2]. - The promotion of combination formulations like Sitagliptin Metformin Tablets can enhance therapeutic effects and simplify medication regimens, improving patient adherence [2]. Group 3: Implementation Timeline - The procurement results for the national Chinese medicine decoction pieces will be implemented in Rizhao City starting April 21, 2025, with 45 varieties available for purchase in public medical institutions [2].

Core Viewpoint - Xianju Pharmaceutical is facing a penalty of 195 million yuan due to alleged price monopoly of dexamethasone phosphate sodium raw materials, which includes confiscation of illegal gains and a fine based on sales revenue [2][6]. Group 1: Company Financials - In 2024, Xianju Pharmaceutical reported a revenue of 4 billion yuan, a decrease of 2.98% year-on-year, and a net profit attributable to shareholders of 397 million yuan, down 29.46% year-on-year [6]. - The company has acknowledged the expected liabilities and related losses in its annual report due to the administrative penalty [6]. Group 2: Product Pricing and Market Impact - The price of dexamethasone phosphate sodium injection has seen significant fluctuations, with a reported increase in sales price from 0.63 yuan to 9.8 yuan, marking a 1455.56% increase [2]. - The hanging network prices for Xianju Pharmaceutical's dexamethasone phosphate sodium injection were adjusted multiple times, with recent prices set at 1.87 yuan and 1.03 yuan, reflecting a nearly 91% decrease [4]. - Xianju Pharmaceutical's dexamethasone phosphate sodium injection was not selected in the national centralized procurement, with the lowest winning price being 2.3 yuan per box [5]. Group 3: Regulatory and Market Context - The company is under scrutiny for its pricing practices, as evidenced by a previous case involving another company that faced penalties for price gouging of the same drug [2]. - The national drug procurement policy has significantly impacted the sales revenue of Xianju Pharmaceutical's products, particularly for common drugs like dexamethasone phosphate sodium injection [6].

Core Viewpoint - In 2024, Kangyuan Pharmaceutical (600557) reported a decline in both revenue and net profit, primarily due to the underperformance of its core products, namely Rendu Ning Injection and Ginkgo Biloba Terpene Lactone Injection [1][5][8] Financial Performance - The company's revenue for 2024 was approximately 3.90 billion yuan, a year-on-year decrease of 19.86% [2][5] - The net profit attributable to shareholders was about 391.86 million yuan, down 15.58% from the previous year [2][5] - Quarterly revenue and net profit showed a downward trend throughout 2024, with Q4 revenue declining by 42.38% and net profit by 69.71% year-on-year [5][6] Product Performance - The main revenue source, injections, generated approximately 1.34 billion yuan in 2024, a decrease of 38.33% year-on-year, largely due to falling sales of Rendu Ning Injection and Ginkgo Biloba Terpene Lactone Injection [8][9] - Rendu Ning Injection's production decreased by 10.24%, with sales down 30.98%, leading to a significant increase in inventory [8][9] - Ginkgo Biloba Terpene Lactone Injection saw a production drop of 33.9% and a sales decline of 47.86% [8][9] Strategic Initiatives - In response to declining sales, the company is expanding its product lineup with new offerings such as Jinzhen Oral Liquid and Xingbei Cough Granules [1][9] - The company completed the acquisition of Jiangsu Zhongxin Pharmaceutical Co., Ltd. in 2024, although this acquisition has not yet turned profitable and is expected to impact short-term performance [1][10][11] Industry Context - The pharmaceutical manufacturing industry is facing external pressures such as healthcare payment reforms, drug price governance, and centralized procurement, leading to a decline in profit margins [6][9] - The company plans to forgo cash dividends for 2024, instead opting for a share buyback strategy, which is viewed as a form of returning value to shareholders [6][10]

浙江海森药业股份有限公司 Zhejiang Haisen Pharmaceutical Co., Ltd. 首次公开发行股票并在主板上市 招股说明书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 （浙江省东阳市六石街道香潭村） 浙江海森药业股份有限公司 招股说明书 1 发行股票类型： 人民币普通股（A 股） 发行股数： 本次拟发行股票数量 1,700 万股，且占本次发行后总 股本的 25%；本次发行不进行原股东公开发售股份 每股面值： 人民币 1.00 元 每股发行价格： 人民币 44.48 元 预计发行日期： 2023 年 3 月 28 日 拟上市的证券交易所和板块： 深圳证券交易所主板 发行后总股本： 6,800 万股 保荐人（主承销商）： 中信证券股份有限公司 招股说明书签署日期： 2023 年 4 月 3 日 本次发行概况 浙江海森药业股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行人注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈 利能力、投资价值或者对投资者的收益作出实质性判 ...

首次公开发行股票并在主板上市 招股意向书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 浙江海森药业股份有限公司 Zhejiang Haisen Pharmaceutical Co., Ltd. （浙江省东阳市六石街道香潭村） 浙江海森药业股份有限公司 招股意向书 1 发行股票类型： 人民币普通股（A 股） 发行股数： 本次拟发行股票数量 1,700 万股，且占本次发行后总 股本的 25%；本次发行不进行原股东公开发售股份 每股面值： 人民币 1.00 元 每股发行价格： 人民币【】元 预计发行日期： 2023 年 3 月 28 日 拟上市的证券交易所和板块： 深圳证券交易所主板 发行后总股本： 6,800 万股 保荐人（主承销商）： 中信证券股份有限公司 招股意向书签署日期： 2023 年 3 月 20 日 本次发行概况 浙江海森药业股份有限公司 招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行人注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈 利能力、投资价值或者对投资者的收益作出实质性判断或保证 ...

首次公开发行股票并在主板上市 招股说明书 （注册稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 浙江海森药业股份有限公司 Zhejiang Haisen Pharmaceutical Co., Ltd. （浙江省东阳市六石街道香潭村） 浙江海森药业股份有限公司 首次公开发行股票招股说明书（注册稿） 发行人声明 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本招股说明 书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正式公告的招股 说明书作为投资决定的依据。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行人注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈 利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反的声明均 属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行人自行 负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发行 后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 浙江海森药业股份有限公司 ...

浙江海森药业股份有限公司 Zhejiang Haisen Pharmaceutical Co., Ltd. （浙江省东阳市六石街道香潭村） 首次公开发行股票并在主板上市 招股说明书 （上会稿） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 保荐人（主承销商） 浙江海森药业股份有限公司 首次公开发行股票招股说明书（上会稿） 发行人声明 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本招股说明 书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正式公告的招股 说明书作为投资决定的依据。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行人注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈 利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反的声明均 属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行人自行 负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发行 后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 浙江海森药业股份有限公司 ...

首次公开发行股票并在主板上市 招股说明书 Zhejiang Haisen Pharmaceutical Co., Ltd. （浙江省东阳市六石街道香潭村） （申报稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 浙江海森药业股份有限公司 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本招股说明 书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正式公告的招股 说明书作为投资决定的依据。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行人注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈 利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反的声明均 属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行人自行 负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发行 后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 浙江海森药业股份有限公司 首次公开发行股票招股说明书（申报稿） | 本次发行概况 | | --- | ...